BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25533565)

  • 1. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes.
    Reiband HK; Schmidt S; Ranjan A; Holst JJ; Madsbad S; Nørgaard K
    Diabetes Metab Res Rev; 2015 Oct; 31(7):672-9. PubMed ID: 25533565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
    Bally L; Thabit H; Hovorka R
    Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closed-loop system in the management of diabetes: past, present, and future.
    Shah VN; Shoskes A; Tawfik B; Garg SK
    Diabetes Technol Ther; 2014 Aug; 16(8):477-90. PubMed ID: 25072271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.
    Taleb N; Emami A; Suppere C; Messier V; Legault L; Ladouceur M; Chiasson JL; Haidar A; Rabasa-Lhoret R
    Diabetologia; 2016 Dec; 59(12):2561-2571. PubMed ID: 27704167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.
    Ranjan A
    Dan Med J; 2018 Feb; 65(2):. PubMed ID: 29393039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
    Haidar A; Rabasa-Lhoret R; Legault L; Lovblom LE; Rakheja R; Messier V; D'Aoust É; Falappa CM; Justice T; Orszag A; Tschirhart H; Dallaire M; Ladouceur M; Perkins BA
    J Clin Endocrinol Metab; 2016 Jan; 101(1):214-23. PubMed ID: 26523526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Pontiroli AE; Ceriani V
    Diabetes Obes Metab; 2018 Aug; 20(8):1812-1816. PubMed ID: 29652110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.
    Castle JR; Engle JM; El Youssef J; Massoud RG; Yuen KC; Kagan R; Ward WK
    Diabetes Care; 2010 Jun; 33(6):1282-7. PubMed ID: 20332355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counterregulatory hormones in insulin-treated diabetic patients admitted to an accident and emergency department with hypoglycaemia.
    Hvidberg A; Christensen NJ; Hilsted J
    Diabet Med; 1998 Mar; 15(3):199-204. PubMed ID: 9545120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon.
    Shirin A; Della Rossa F; Klickstein I; Russell J; Sorrentino F
    PLoS One; 2019; 14(3):e0213665. PubMed ID: 30893335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy.
    Schiel R; Ulbrich S; Müller UA
    Diabetes Metab; 1998 Dec; 24(6):509-14. PubMed ID: 9932217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing hypoglycaemia with insulin analogues.
    Heller S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive insulin therapy in patients with type 1 diabetes mellitus.
    Switzer SM; Moser EG; Rockler BE; Garg SK
    Endocrinol Metab Clin North Am; 2012 Mar; 41(1):89-104. PubMed ID: 22575408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L; Baker DE; Davis SN; Ratner RE
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.
    Taleb N; Haidar A; Messier V; Gingras V; Legault L; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 Jan; 19(1):13-23. PubMed ID: 27629286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Islet α cells and glucagon--critical regulators of energy homeostasis.
    Campbell JE; Drucker DJ
    Nat Rev Endocrinol; 2015 Jun; 11(6):329-38. PubMed ID: 25850661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.